You Can Forget About Seeing This Drug Work

The third time isn't the charm for Medivation (Nasdaq: MDVN  ) and Pfizer's (NYSE: PFE  ) Dimebon -- not that anyone thought that it was.

Nearly two years ago, Dimebon failed to show an effect in Alzheimer's disease; patients actually fared worse for some measures.

Last year, the drug failed again, this time in Huntington's disease, another neurological disease.

Back to Alzheimer's disease today, in a trial called CONCERT, with the same result. Combining Dimebon with Aricept, sold by Eisai and Pfizer, didn't help patients any more than Aricept alone. No melding symphony in this CONCERT.

Maybe Medivation and Pfizer should have ended Dimebon's development earlier, but this trial was already ongoing when the first trial failed. As I said when Dimebon failed in Huntington's disease, the CONCERT trial acted as a call option for investors with a huge upside and very little downside. Everyone was expecting it to fail; Medivation's value is entirely tied up in its prostate cancer drug MDV3100, which has seen much better success than Dimebon.

Unfortunately call options often expire worthless. So do partnerships; the companies are cutting their losses -- finally -- shutting down the Dimebon program, and going their separate ways.

For better or worse, Pfizer still has a hand in Alzheimer's disease. Bapineuzumab, its most advanced Alzheimer's drug, was acquired in its purchase of Wyeth; Johnson & Johnson (NYSE: JNJ  ) and Elan (NYSE: ELN  ) split the other half. There are higher hopes for bapineuzumab than there were for Dimebon, but only mildly so.

Alzheimer's disease is hard to treat in large part because we really don't know what causes it. Bapineuzumab is supposed to work by inhibiting the formation of amyloid plaques, the same basic theory, although through a different mechanism, as Eli Lilly's (NYSE: LLY  ) semagacestat, which failed to help Alzheimer's patients. Lilly has another phase 3 Alzheimer's drug in development, so it has another shot to succeed (and another shot to fail).

Failing is a theme with Alzheimer's drugs, making them appropriate only for very risk-tolerant investors or those that like the rest of the pipeline and assign zero value to the Alzheimer's programs. If you're looking for something a little more stable -- something more appropriate for a retirement account perhaps -- check out the Fool's new free report, "3 Stocks That Will Help You Retire Rich."

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Pfizer, Johnson & Johnson, and Elan and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 18, 2012, at 7:07 AM, starson wrote:

    I was fascinated to discover that there's been research on saffron versus Aricept (donepezil). Check it out: http://nutritionfacts.org/videos/saffron-versus-aricept/. (noncommercial, science-based site) According to the findings, saffron works just as well (which isn't all that well, though better than placebo). And without the side effects.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1759352, ~/Articles/ArticleHandler.aspx, 11/25/2014 8:43:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement